1Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage Ⅲ B melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses [ J ]. J Clin Oncol, 2006, 24:3164-3171.
2Kirkwood JM, Strawderman MH, Emstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684[ J]. J Clin Oncol, 1996, 14(1 ):7- 17.
3Gogas H, Dafni U, Bafaloukos D, et al. A randomized phase Ⅲ trial of 1 month versus 1 year adjuvant high-dose interferon alfa- 2b in patients with resected high risk melanoma[J]. J Clin Oncol, 2007, 25(18Suppl) :8505.
4Eggermont AM, Suciu S, Santinami W, et al. EORTC18991 : Long-term adjuvant pegylated intefferon-alpha2b (PEG-IFN) compared to observation in resected stage Ⅲ melanoma, final resuits of a randomized phase Ⅲ trial[J]. J Clin Oncol, 2007, 25 (18Suppl) :8504.
5Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma [ J ]. N Engl J Med, 2006, 355:1307 - 1317.
6Essner R. Surgical treatment of malignant melanoma [ J ]. Surg Clin North Am, 2003, 83( 1 ) :109 -156.
7Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase Ⅲ study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [ J ]. J Clin Oncol, 2000, 18:158 - 166.
8Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase Ⅲ, multicenter study from the Dermatologic Cooperative Oncology Group[ J]. J Clin Oncol, 2005, 23:9001 -9007.
9Hwu W J, Panageas KS, Menell JH, et al. Phase Ⅱ study of temozolomide plus pegylated intefferon-alpha-2b for metastatic melanoma [ J ]. Cancer, 2006,106:2445 - 2451.
10Hwu W J, Krown SE, Menell JH, et al. Phase Ⅱ study of temozolomide plus thalidomide for the treatment of metastatic melanoma[J]. J Clin Oncol, 2003, 21:3351 -3356.
同被引文献264
1Jing-Ting Jiang, Chang-Ping Wu, Lu-Jun Chen, Xiao Zheng, Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China Yi-Bei Zhu, Jing Sun, Xue-Guang Zhang, Key Laboratory of Stem Cell of Jiangsu Province, Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, Jiangsu Province, China Yue-Ping Shen, Wen-Xiang Wei, Department of Medicine, Soochow University, Suzhou 215123, Jiangsu Province, China Bin-Feng Lu, Department of Immunology, University of Pitts- burgh School of Medicine, Pittsburgh, PA 15261, United States.Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J].World Journal of Gastroenterology,2010,16(48):6155-6162. 被引量：83
